论文部分内容阅读
目的对恩替卡韦与鳖甲软肝片联合应用于失代偿期乙型肝炎e抗原(HBe Ag)阳性肝硬化的临床效果进行分析。方法 56例失代偿期HBe Ag阳性肝硬化患者,随机分为治疗组和对照组,各28例。对照组给予恩替卡韦治疗,治疗组在此基础上联合鳖甲软肝片治疗,对比两组的临床效果。结果治疗组的肝硬化与肝纤维化指标均明显优于对照组,差异均有统计学意义(P<0.05)。结论采用恩替卡韦与鳖甲软肝片治疗失代偿期HBe Ag阳性肝硬化,可有效控制患者病情的进一步发展。
Objective To analyze the clinical effects of entecavir and Biejia Ruangan Pian on decompensated hepatitis B e antigen (HBeAg) -positive cirrhosis. Methods 56 patients with decompensated HBeAg-positive cirrhosis were randomly divided into treatment group and control group, 28 cases in each. The control group was treated with entecavir. On the basis of this, the treatment group was treated with Biejia Ruangan Pian, compared with the clinical effect of the two groups. Results The indexes of liver cirrhosis and liver fibrosis in the treatment group were significantly better than those in the control group (P <0.05). Conclusion Entecavir and Biejia Ruangan Tablet in the treatment of decompensated HBeAg-positive cirrhosis can effectively control the further development of the patient’s condition.